AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

by Kyle | Jul 21, 2022 | Press Release

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been...

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

by Kyle | Jul 12, 2022 | Press Release

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State...

AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

by IR Team | Jun 2, 2022 | Press Release

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide doctors, researchers...

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

by Kyle | May 24, 2022 | Press Release

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed...

AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

by Kyle | May 10, 2022 | Press Release

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample...

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

by Kyle | Apr 27, 2022 | Press Release

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a...